Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Taxes (2017 - 2020)

Avalo Therapeutics filings provide 4 years of Change in Taxes readings, the most recent being $839000.0 for Q2 2020.

  • On a quarterly basis, Change in Taxes rose 298.73% to $839000.0 in Q2 2020 year-over-year; TTM through Mar 2021 was $839000.0, a 146.25% increase, with the full-year FY2020 number at $288000.0, up 119.45% from a year prior.
  • Change in Taxes hit $839000.0 in Q2 2020 for Avalo Therapeutics, up from -$551000.0 in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $3.2 million in Q3 2017 to a low of -$970852.0 in Q4 2017.
  • Median Change in Taxes over the past 4 years was -$190199.0 (2018), compared with a mean of $69972.6.
  • Biggest five-year swings in Change in Taxes: tumbled 3040.65% in 2019 and later surged 298.73% in 2020.
  • Avalo Therapeutics' Change in Taxes stood at -$970852.0 in 2017, then soared by 83.23% to -$162790.0 in 2018, then plummeted by 184.28% to -$462783.0 in 2019, then surged by 281.29% to $839000.0 in 2020.
  • The last three reported values for Change in Taxes were $839000.0 (Q2 2020), -$551000.0 (Q1 2020), and -$462783.0 (Q4 2019) per Business Quant data.